news_6

Osel Announces Positive Results from Phase 1b Trial of Live Biotherapeutic Product CBM588 in Combination with Checkpoint Inhibitor (CPI) Therapy in Metastatic Renal Cell Carcinoma

-- CBM588 plus nivolumab/ipilimumab improved ORR and PFS compared to nivolumab/ipilimumab alone -- -- First randomized study to prospectively assess...

news_6

IASO Biotherapeutics Application for Clinical Trials of the Second Indication of its Fully Human CD19/CD22 Dual-targeted CAR-T Drug Accepted by NMPA

PLEASANTON, Calif. & NANJING, China--(BUSINESS WIRE)--#Biopharmaceutical--IASO Biotherapeutics, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell...